APA (7th ed.) Citation

Neubauer, A., Wiesmann, T., Vogelmeier, C. F., Mack, E., Skevaki, C., Gaik, C., . . . Burchert, A. (2020). Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia, 34(8), 2276-2278. https://doi.org/10.1038/s41375-020-0907-9

Chicago Style (17th ed.) Citation

Neubauer, Andreas, et al. "Ruxolitinib for the Treatment of SARS-CoV-2 Induced Acute Respiratory Distress Syndrome (ARDS)." Leukemia 34, no. 8 (2020): 2276-2278. https://doi.org/10.1038/s41375-020-0907-9.

MLA (9th ed.) Citation

Neubauer, Andreas, et al. "Ruxolitinib for the Treatment of SARS-CoV-2 Induced Acute Respiratory Distress Syndrome (ARDS)." Leukemia, vol. 34, no. 8, 2020, pp. 2276-2278, https://doi.org/10.1038/s41375-020-0907-9.